MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Kodu・Aktsiate loetelu・Collegium Pharmaceutical Inc

C
Collegium Pharmaceutical Inc

Suletud

SektorTervishoid

46.07 -1.71

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

45.69

Max

47.06

Põhinäitajad
By Trading Economics
Sissetulek	20M 32M
Müük	21M 209M
P/E Sektori keskmine	30.356 88.032
Kasumimarginaal	15.049
Töötajad	357
EBITDA	28M 122M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+6.09% upside

Turustatistika
By TradingEconomics
Turukapital	427M 1.6B
Eelmine avamishind	47.78
Eelmine sulgemishind	46.07

Uudiste sentiment

By Acuity

16%

84%

21 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

27.09 / 27.6 Toetus ja vastupanu

Collegium Pharmaceutical Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. dets 2025, 22:20 UTC

Suurimad hinnamuutused turgudel

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31. dets 2025, 17:31 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31. dets 2025, 16:30 UTC

Suurimad hinnamuutused turgudel

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31. dets 2025, 15:19 UTC

Suurimad hinnamuutused turgudel

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31. dets 2025, 15:17 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31. dets 2025, 14:37 UTC

Suurimad hinnamuutused turgudel

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31. dets 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31. dets 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31. dets 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31. dets 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31. dets 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31. dets 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31. dets 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31. dets 2025, 17:16 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31. dets 2025, 17:00 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31. dets 2025, 15:57 UTC

Omandamised, ülevõtmised, äriostud

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31. dets 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31. dets 2025, 15:02 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1M of Shares

31. dets 2025, 14:40 UTC

Omandamised, ülevõtmised, äriostud

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31. dets 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31. dets 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31. dets 2025, 13:01 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31. dets 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31. dets 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31. dets 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31. dets 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31. dets 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Collegium Pharmaceutical Inc Prognoos

Hinnasiht

By TipRanks

6.09% tõus

12 kuu keskmine prognoos

Keskmine 50 USD 6.09%

Kõrge 58 USD

Madal 46 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Collegium Pharmaceutical Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Collegium Pharmaceutical Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

27.09 / 27.6Toetus ja vastupanu

Bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

21 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.